Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival

Mrinal M Patnaik, Domenica Caramazza, Naseema Gangat, Curtis A. Hanson, Animesh D Pardanani, Ayalew Tefferi

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Objectives: The current study was designed to identify International Prognostic Scoring System (IPSS)-independent prognostic factors in young patients with primary myelofibrosis (PMF). The study also examined the overall risk profile of long-term (>15 yr) and short-term (<5 yr) survivors. Methods: Study patients were selected from the Mayo Clinic database for PMF, and study eligibility included age <60 yr, minimum follow-up of 5 yr and availability of IPSS-relevant variables at time of diagnosis. Results: A total of 148 consecutive patients met the above-stipulated criteria. To date, 89 (60%) patients have died; 48 (32%) died within 5 yr of their diagnosis (short-term survivors). Median follow-up of patients who are alive was 9 yr (range 5-28) with a >15-yr survival documented in 16 patients (long-term survivors). Multivariable analysis identified unfavorable IPSS category (intermediate-2/high risk), age >50 yr and platelet count <100 × 109/L as independent predictors of inferior survival (P < 0.01). Median survival in the absence of all three risk factors was approximately 18 yr and was shortened to 7 and 1.6 yr in the presence of 1 or ≥2 risk factors, respectively (P < 0.01). Among long-term survivors, 69% were age ≤50 yr, 100% had favorable IPSS profile and 100% displayed platelet count ≥100 × 109/L; the corresponding figures for short-term survivors were 29%, 50% and 65% (P < 0.01). Conclusions: Age and platelet count are IPSS-independent predictors of survival in young patients with PMF, and they complement the IPSS in identifying patients with very long or very short survival.

Original languageEnglish (US)
Pages (from-to)105-108
Number of pages4
JournalEuropean Journal of Haematology
Volume84
Issue number2
DOIs
StatePublished - Feb 2010

Fingerprint

Primary Myelofibrosis
Platelet Count
Survival
Survivors

Keywords

  • Myelofibrosis
  • Prognosis
  • Survival
  • Young

ASJC Scopus subject areas

  • Hematology

Cite this

@article{391e898befb642fbb741e3d1b616438e,
title = "Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival",
abstract = "Objectives: The current study was designed to identify International Prognostic Scoring System (IPSS)-independent prognostic factors in young patients with primary myelofibrosis (PMF). The study also examined the overall risk profile of long-term (>15 yr) and short-term (<5 yr) survivors. Methods: Study patients were selected from the Mayo Clinic database for PMF, and study eligibility included age <60 yr, minimum follow-up of 5 yr and availability of IPSS-relevant variables at time of diagnosis. Results: A total of 148 consecutive patients met the above-stipulated criteria. To date, 89 (60{\%}) patients have died; 48 (32{\%}) died within 5 yr of their diagnosis (short-term survivors). Median follow-up of patients who are alive was 9 yr (range 5-28) with a >15-yr survival documented in 16 patients (long-term survivors). Multivariable analysis identified unfavorable IPSS category (intermediate-2/high risk), age >50 yr and platelet count <100 × 109/L as independent predictors of inferior survival (P < 0.01). Median survival in the absence of all three risk factors was approximately 18 yr and was shortened to 7 and 1.6 yr in the presence of 1 or ≥2 risk factors, respectively (P < 0.01). Among long-term survivors, 69{\%} were age ≤50 yr, 100{\%} had favorable IPSS profile and 100{\%} displayed platelet count ≥100 × 109/L; the corresponding figures for short-term survivors were 29{\%}, 50{\%} and 65{\%} (P < 0.01). Conclusions: Age and platelet count are IPSS-independent predictors of survival in young patients with PMF, and they complement the IPSS in identifying patients with very long or very short survival.",
keywords = "Myelofibrosis, Prognosis, Survival, Young",
author = "Patnaik, {Mrinal M} and Domenica Caramazza and Naseema Gangat and Hanson, {Curtis A.} and Pardanani, {Animesh D} and Ayalew Tefferi",
year = "2010",
month = "2",
doi = "10.1111/j.1600-0609.2009.01373.x",
language = "English (US)",
volume = "84",
pages = "105--108",
journal = "European Journal of Haematology",
issn = "0902-4441",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival

AU - Patnaik, Mrinal M

AU - Caramazza, Domenica

AU - Gangat, Naseema

AU - Hanson, Curtis A.

AU - Pardanani, Animesh D

AU - Tefferi, Ayalew

PY - 2010/2

Y1 - 2010/2

N2 - Objectives: The current study was designed to identify International Prognostic Scoring System (IPSS)-independent prognostic factors in young patients with primary myelofibrosis (PMF). The study also examined the overall risk profile of long-term (>15 yr) and short-term (<5 yr) survivors. Methods: Study patients were selected from the Mayo Clinic database for PMF, and study eligibility included age <60 yr, minimum follow-up of 5 yr and availability of IPSS-relevant variables at time of diagnosis. Results: A total of 148 consecutive patients met the above-stipulated criteria. To date, 89 (60%) patients have died; 48 (32%) died within 5 yr of their diagnosis (short-term survivors). Median follow-up of patients who are alive was 9 yr (range 5-28) with a >15-yr survival documented in 16 patients (long-term survivors). Multivariable analysis identified unfavorable IPSS category (intermediate-2/high risk), age >50 yr and platelet count <100 × 109/L as independent predictors of inferior survival (P < 0.01). Median survival in the absence of all three risk factors was approximately 18 yr and was shortened to 7 and 1.6 yr in the presence of 1 or ≥2 risk factors, respectively (P < 0.01). Among long-term survivors, 69% were age ≤50 yr, 100% had favorable IPSS profile and 100% displayed platelet count ≥100 × 109/L; the corresponding figures for short-term survivors were 29%, 50% and 65% (P < 0.01). Conclusions: Age and platelet count are IPSS-independent predictors of survival in young patients with PMF, and they complement the IPSS in identifying patients with very long or very short survival.

AB - Objectives: The current study was designed to identify International Prognostic Scoring System (IPSS)-independent prognostic factors in young patients with primary myelofibrosis (PMF). The study also examined the overall risk profile of long-term (>15 yr) and short-term (<5 yr) survivors. Methods: Study patients were selected from the Mayo Clinic database for PMF, and study eligibility included age <60 yr, minimum follow-up of 5 yr and availability of IPSS-relevant variables at time of diagnosis. Results: A total of 148 consecutive patients met the above-stipulated criteria. To date, 89 (60%) patients have died; 48 (32%) died within 5 yr of their diagnosis (short-term survivors). Median follow-up of patients who are alive was 9 yr (range 5-28) with a >15-yr survival documented in 16 patients (long-term survivors). Multivariable analysis identified unfavorable IPSS category (intermediate-2/high risk), age >50 yr and platelet count <100 × 109/L as independent predictors of inferior survival (P < 0.01). Median survival in the absence of all three risk factors was approximately 18 yr and was shortened to 7 and 1.6 yr in the presence of 1 or ≥2 risk factors, respectively (P < 0.01). Among long-term survivors, 69% were age ≤50 yr, 100% had favorable IPSS profile and 100% displayed platelet count ≥100 × 109/L; the corresponding figures for short-term survivors were 29%, 50% and 65% (P < 0.01). Conclusions: Age and platelet count are IPSS-independent predictors of survival in young patients with PMF, and they complement the IPSS in identifying patients with very long or very short survival.

KW - Myelofibrosis

KW - Prognosis

KW - Survival

KW - Young

UR - http://www.scopus.com/inward/record.url?scp=74049116496&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74049116496&partnerID=8YFLogxK

U2 - 10.1111/j.1600-0609.2009.01373.x

DO - 10.1111/j.1600-0609.2009.01373.x

M3 - Article

C2 - 19895568

AN - SCOPUS:74049116496

VL - 84

SP - 105

EP - 108

JO - European Journal of Haematology

JF - European Journal of Haematology

SN - 0902-4441

IS - 2

ER -